U.S. markets open in 9 hours 13 minutes
  • S&P Futures

    4,159.25
    -5.50 (-0.13%)
     
  • Dow Futures

    33,982.00
    -34.00 (-0.10%)
     
  • Nasdaq Futures

    13,902.50
    -16.75 (-0.12%)
     
  • Russell 2000 Futures

    2,228.70
    -9.70 (-0.43%)
     
  • Crude Oil

    61.10
    -0.25 (-0.41%)
     
  • Gold

    1,793.50
    +0.40 (+0.02%)
     
  • Silver

    26.58
    +0.01 (+0.02%)
     
  • EUR/USD

    1.2037
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.5640
    +0.0020 (+0.13%)
     
  • Vix

    17.50
    -1.18 (-6.32%)
     
  • GBP/USD

    1.3933
    +0.0001 (+0.01%)
     
  • USD/JPY

    107.9890
    -0.0540 (-0.05%)
     
  • BTC-USD

    54,116.29
    -1,941.55 (-3.46%)
     
  • CMC Crypto 200

    1,248.23
    -14.73 (-1.17%)
     
  • FTSE 100

    6,895.29
    +35.42 (+0.52%)
     
  • Nikkei 225

    29,068.13
    +559.58 (+1.96%)
     

Amgen edges up on trial results

The biotech firm edged up 0.6% to 138.69 after reporting positive results from its phase three trial of evolocumab in combination with statins in Japanese patients. Amgen's (AMGN) evolocumab is an injectable cholesterol fighter for patients whose bodies can't tolerate statins such as Pfizer's (PFE) Lipitor. On Thu., Amgen said it had filed an application with U.S. health regulators to sell evolocumab, beating out competitor Regeneron (REGN) to be the 1st to seek approval in the U.S. Regeneron shares fell 0.9% to 346.92. Pfizer shares fell 0.4% to 29.38.